This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Karlsson, A.
Right arrow Articles by Eriksson, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Karlsson, A.
Right arrow Articles by Eriksson, K.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, March 2007, p. 328-330, Vol. 14, No. 3
1071-412X/07/$08.00+0     doi:10.1128/CVI.00349-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Ability of Monocyte-Derived Dendritic Cells To Secrete Oxygen Radicals in Response to Formyl Peptide Receptor Family Agonists Compared to That of Myeloid and Plasmacytoid Dendritic Cells{triangledown}

Anna Karlsson, Erik Nygren,{dagger} Jennie Karlsson, Inger Nordström, Claes Dahlgren, and Kristina Eriksson*

Department of Rheumatology and Inflammation Research, Göteborg University, Göteborg, Sweden

Received 13 September 2006/ Returned for modification 7 November 2006/ Accepted 28 December 2006


arrow
ABSTRACT
 
We show that human monocyte-derived dendritic cells (DC) differ considerably from freshly isolated blood-derived myeloid and plasmacytoid DC in their abilities to produce reactive oxygen species in response to different agonists to the formyl peptide receptor family and are thus poor representatives of blood DC in this field of research.


arrow
TEXT
 
Increasing evidence suggests that reactive oxygen species (ROS) have important signaling properties in many cells, including dendritic cells (DC). ROS affect the maturation state, the production and secretion of cytokines, and the antigen-presenting capacity of DC, and the cells become functionally more efficient when exposed to ROS (1, 11, 13, 16). Like monocytes and neutrophils, for example, DC are equipped with a membrane-localized electron transport system, NADPH-oxidase, that reduces molecular oxygen to superoxide anions at the expense of NADPH (6, 11, 17). Activation of DC may thus initiate/include ROS-mediated autocrine/paracrine regulatory functions. NADPH-oxidase is activated by a large number of receptor-binding agonists, including particles that trigger phagocytosis, chemoattractants, and other "danger molecules." The precise receptor repertoire thus determines the responsiveness of the cells to a particular agonist.

DC represent a heterogeneous population of leukocytes derived from several different progenitors, which also have different functional properties, depending on their maturation status (3, 8, 9). Due to the scarcity of DC in human blood, most functional studies of DC are made with in vitro-generated monocyte-derived DC (moDC). However, expression of pathogen recognition receptors on DC may vary according to their hematopoietic origins and degrees of maturation. We therefore set out to characterize the abilities of human DC of different origins to respond to three formyl peptide receptor (FPR) family agonists; fMLF (N-formyl-Met-Leu-Phe), WKYMVm (Trp-Lys-Tyr-Met-Val-D-Met-NH2), and WKYMVM (Trp-Lys-Tyr-Met-Val-L-Met-NH2) (7). The human FPR family consists of three receptors, FPR, FPR-like receptor 1 (FPRL1), and FPRL2, which are all expressed on moDC (18-20). FPR is a high-affinity receptor for formyl peptides but can also be activated by WKYMVm. FPRL1 is a promiscuous receptor that can be activated by numerous and chemically unrelated ligands, including WKYMVm and WKYMVM, and this receptor can also bind fMLF with low affinity. FPRL2 has a low affinity for several FPRL1 ligands, e.g., WKYMVm and WKYMVM, but it does not bind fMLF (4, 7).

Human plasmacytoid DC (pDC), myeloid DC (mDC), and monocytes were isolated from peripheral blood mononuclear cells, using a BDCA-4 cell isolation kit, a CD1c (BDCA-1) dendritic cell isolation kit, and CD14 microbeads (all from Miltenyi Biotec GmbH, Bergisch Gladbach, Germany), respectively. ROS responses in monocytes and DC to the FPR family agonists fMLF (Sigma Chemical Co., St. Louis, MO), WKYMVm, and WKYMVM (both synthesized and HPLC-purified; Alta Bioscience, University of Birmingham, UK) were measured by luminol-enhanced chemiluminescence (CL) as previously described (5), using 4 x 104 cells for each experiment.

All three FPR family agonists induced responses in both mDC and pDC, but the overall strength of the responses was severalfold higher in mDC than in pDC (Table 1). The responses differed very little between the cell types, however, with respect to the relative responsiveness among the three agonists (Fig. 1A and B and Table 1) and the kinetics of the agonist-specific responses (Fig. 2). Thus, WKYMVm, which binds all three human FPR family receptors (FPR, FPRL1, and FPRL2), was the strongest agonist for both mDC and pDC, with 50% inhibitory concentration (IC50) values of 13 and 3.7 nM, respectively. The FPR agonist fMLF had a three-times-lower IC50 value than the FPRL1/FPRL2 agonist WKYMVM in both cell types.


View this table:
[in this window]
[in a new window]

  		TABLE 1. Maximal peak values of chemoattractant-induced NADPH-oxidase responses in monocytes and dendritic cells


Figure 1
View larger version (24K):
[in this window]
[in a new window]

  		FIG. 1. Dose responses of NADPH-oxidase activity induced by FPR family agonists in purified human DC and monocytes. Human mDC (A), pDC (B), and monocytes (C) purified from peripheral blood were stimulated with different concentrations of fMLF, WKYMVm, or WKYMVM, and superoxide release was measured by luminol-enhanced CL. The figures show the mean peak CL responses at different concentrations of each agonist, given as percentages of the maximal CL response (achieved at different concentrations for the different agonists). The figure also shows the IC50 value for each agonist, calculated as described by Christophe et al. (4).


Figure 2
View larger version (21K):
[in this window]
[in a new window]

  		FIG. 2. NADPH-oxidase responses in mDC, pDC, and moDC. Purified mDC (A), pDC (B), and cultured, monocyte-derived moDC (C) were stimulated with 1 µM fMLF, WKYMVm, or WKYMVM, and superoxide (O2–) release was measured continuously by CL. The insets show mean peak values (n = 3) of the CL responses as percentages of the responses to WKYMVm.

Compared to that in monocytes, however, ROS responses in mDC and pDC differed with respect to strength and sensitivity as well as to the relative responsiveness to the three agonists, implying that DC and monocytes differ in their FPR densities and/or distributions (Table 1 and Fig. 1C). Monocytes displayed an overall-higher level of responsiveness than DC (Table 1). Like DC, monocytes had the strongest response to WKYMVm, of which the 50% effective concentration was 1 nM. Furthermore, fMLF and WKYMVM were equally efficient at inducing ROS responses in monocytes (while fMLF was a stronger agonist in DC) and induced peak responses at 5- to 10-times-lower doses than in DC.

The majority of studies of DC-generated ROS production have been performed using in vitro-generated human moDC (1, 10, 12, 14). Since moDC differ from mDC in several aspects, we wanted to investigate whether moDC are representative of in vivo DC with respect to FPR family agonist-induced ROS responses. Isolated monocytes were therefore cultured for 7 days with recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) (800 U/ml; Leucomax; Sherring Plough) and recombinant human interleukin-4 (500 U/ml; R&D) before being analyzed. We found that moDC have an impaired response to fMLF and perhaps also to WKYMVM compared to those for mDC (Table 1 and Fig. 2), even though both mDC and moDC responded strongly to WKYMVm. One explanation for this could be that mDC express higher levels or a different composition of FPR family receptors than moDC. Furthermore, it was evident from comparing moDC to monocytes that the 7-day culture in GM-CSF-containing medium led to severely impaired responses to both WKYMVM and fMLF and a partially impaired response to WKYMVm, implying that the in vitro culture profoundly down-modulates the expression of at least some of the FPR family receptors. Other studies have shown that many other pathogen recognition molecules, e.g., the Toll-like receptors 1, 2, 4, and 5, which are present in monocytes and mDC, are virtually absent in moDC (15). An alternative (or complementing) explanation could be that the 7-day culture leads to a decrease in the amount and/or function of NADPH-oxidase.

Our data show that directly isolated human mDC and pDC exhibit similar levels of ROS responsiveness to the three FPR family receptor agonists tested. However, in vitro-generated moDC differed considerably from in vivo DC in their responses to these agonists and are thus not universal substitutes for mDC in this field of research. This is to our knowledge the first study to show not only that directly isolated immature human mDC and pDC can respond to FPR agonists but also that mDC have stronger responses to the agonists tested, even though the relative pattern of responsiveness was almost identical. This is interesting, as mDC and pDC have very different expression levels of other pathogen recognition receptors, such as the Toll-like receptors (9), and also since they belong to two distinct hematopoietic lineages, the myeloid and the lymphoid, respectively (2). Thus, even though mDC are more closely related to monocytes than to pDC, they differ from monocytes but not from pDC in FPR expression.

In our study of FPR family receptor expression and the induced ROS responses of the FPR family, moDC were not an identical substitute for mDC, and they also differed from monocytes. It has previously been shown that propagation of moDC is associated with a specific down-regulation of FPRL1 but not of FPR and FPRL2 (18-20). The NADPH-oxidase components p47phox and gp91phox are also down-regulated during monocyte differentiation to DC (16), which further adds to their diminished responsiveness vis-à-vis monocytes. That pDC can secrete ROS has previously been shown, using purified and interleukin-3-activated pDC (16).

In summary, we found that human monocytes, mDC, and pDC had similar response patterns to FPR family receptor agonists but that the amounts of ROS produced differed considerably, with monocytes producing more than mDC, which produced more than pDC. moDC differed considerably from both monocytes and mDC in that ROS responses were poor in moDC and that these cells had a particularly low ability to respond to fMLF.


arrow
ACKNOWLEDGMENTS
 
These studies were supported by the Swedish Science Council, King Gustaf V's Foundation, and Västra Götalandsregionen through LUA/ALF.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: Department of Rheumatology and Inflammation Research, Guldhedsgatan 10A, 413 46 Göteborg, Sweden. Phone: 46-31-3424761. Fax: 46-31-823925. E-mail: Kristina.Eriksson{at}microbio.gu.se. Back

{triangledown} Published ahead of print on 10 January 2007. Back

{dagger} Present address: Department of Microbiology and Immunology, Göteborg University, Göteborg, Sweden. Back


arrow
REFERENCES
 
    1
  1. Alderman, C. J., S. Shah, J. C. Foreman, B. M. Chain, and D. R. Katz. 2002. The role of advanced oxidation protein products in regulation of dendritic cell function. Free Radic. Biol. Med. 32:377-385. 11864777[CrossRef][Medline]
    2. 2
  2. Banchereau, J., F. Briere, C. Caux, J. Davoust, S. Lebecque, Y. J. Liu, B. Pulendran, and K. Palucka. 2000. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18:767-811. 10837075[CrossRef][Medline]
    3. 3
  3. Cella, M., D. Jarrossay, F. Facchetti, O. Alebardi, H. Nakajima, A. Lanzavecchia, and M. Colonna. 1999. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat. Med. 5:919-923. 10426316[CrossRef][Medline]
    4. 4
  4. Christophe, T., A. Karlsson, C. Dugave, M. J. Rabiet, F. Boulay, and C. Dahlgren. 2001. The synthetic peptide Trp-Lys-Tyr-Met-Val-Met-NH2 specifically activates neutrophils through FPRL1/lipoxin A4 receptors and is an agonist for the orphan monocyte-expressed chemoattractant receptor FPRL2. J. Biol. Chem. 276:21585-21593. 11285256[Abstract/Free Full Text]
    5. 5
  5. Dahlgren, C., and A. Karlsson. 1999. Respiratory burst in human neutrophils. J. Immunol. Methods 232:3-14. 10618505[CrossRef][Medline]
    6. 6
  6. Elsen, S., J. Doussiere, C. L. Villiers, M. Faure, R. Berthier, A. Papaioannou, N. Grandvaux, P. N. Marche, and P. V. Vignais. 2004. Cryptic O2–-generating NADPH oxidase in dendritic cells. J. Cell Sci. 117:2215-2226. 15126623[Abstract/Free Full Text]
    7. 7
  7. Fu, H., J. Karlsson, J. Bylund, C. Movitz, A. Karlsson, and C. Dahlgren. 2006. Ligand recognition and activation of formyl peptide receptors in neutrophils. J. Leukoc. Biol. 79:247-256. 16365159[Free Full Text]
    8. 8
  8. Grouard, G., I. Durand, L. Filgueira, J. Banchereau, and Y. J. Liu. 1996. Dendritic cells capable of stimulating T cells in germinal centres. Nature 384:364-367. 8934523[CrossRef][Medline]
    9. 9
  9. Kadowaki, N., S. Ho, S. Antonenko, R. W. Malefyt, R. A. Kastelein, F. Bazan, and Y. J. Liu. 2001. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J. Exp. Med. 194:863-869. 11561001[Abstract/Free Full Text]
    10. 10
  10. Kantengwa, S., L. Jornot, C. Devenoges, and L. P. Nicod. 2003. Superoxide anions induce the maturation of human dendritic cells. Am. J. Respir. Crit. Care Med. 167:431-437. 12554628[Abstract/Free Full Text]
    11. 11
  11. Matsue, H., D. Edelbaum, D. Shalhevet, N. Mizumoto, C. Yang, M. E. Mummert, J. Oeda, H. Masayasu, and A. Takashima. 2003. Generation and function of reactive oxygen species in dendritic cells during antigen presentation. J. Immunol. 171:3010-3018. 12960326[Abstract/Free Full Text]
    12. 12
  12. Rutault, K., C. Alderman, B. M. Chain, and D. R. Katz. 1999. Reactive oxygen species activate human peripheral blood dendritic cells. Free Radic. Biol. Med. 26:232-238. 9890657[CrossRef][Medline]
    13. 13
  13. Tan, P. H., P. Sagoo, C. Chan, J. B. Yates, J. Campbell, S. C. Beutelspacher, B. M. Foxwell, G. Lombardi, and A. J. George. 2005. Inhibition of NF-kappa B and oxidative pathways in human dendritic cells by antioxidative vitamins generates regulatory T cells. J. Immunol. 174:7633-7644. 15944264[Abstract/Free Full Text]
    14. 14
  14. Verhasselt, V., M. Goldman, and F. Willems. 1998. Oxidative stress up-regulates IL-8 and TNF-alpha synthesis by human dendritic cells. Eur. J. Immunol. 28:3886-3890. 9842932[CrossRef][Medline]
    15. 15
  15. Visintin, A., A. Mazzoni, J. H. Spitzer, D. H. Wyllie, S. K. Dower, and D. M. Segal. 2001. Regulation of Toll-like receptors in human monocytes and dendritic cells. J. Immunol. 166:249-255. 11123299[Abstract/Free Full Text]
    16. 16
  16. Vulcano, M., S. Dusi, D. Lissandrini, R. Badolato, P. Mazzi, E. Riboldi, E. Borroni, A. Calleri, M. Donini, A. Plebani, L. Notarangelo, T. Musso, and S. Sozzani. 2004. Toll receptor-mediated regulation of NADPH oxidase in human dendritic cells. J. Immunol. 173:5749-5756. 15494527[Abstract/Free Full Text]
    17. 17
  17. Werling, D., J. C. Hope, C. J. Howard, and T. W. Jungi. 2004. Differential production of cytokines, reactive oxygen and nitrogen by bovine macrophages and dendritic cells stimulated with Toll-like receptor agonists. Immunology 111:41-52. 14678198[CrossRef][Medline]
    18. 18
  18. Yang, D., Q. Chen, B. Gertz, R. He, M. Phulsuksombati, R. D. Ye, and J. J. Oppenheim. 2002. Human dendritic cells express functional formyl peptide receptor-like-2 (FPRL2) throughout maturation. J. Leukoc. Biol. 72:598-607. 12223529[Abstract/Free Full Text]
    19. 19
  19. Yang, D., Q. Chen, Y. Le, J. M. Wang, and J. J. Oppenheim. 2001. Differential regulation of formyl peptide receptor-like 1 expression during the differentiation of monocytes to dendritic cells and macrophages. J. Immunol. 166:4092-4098. 11238658[Abstract/Free Full Text]
    20. 20
  20. Yang, D., Q. Chen, S. Stoll, X. Chen, O. M. Howard, and J. J. Oppenheim. 2000. Differential regulation of responsiveness to fMLP and C5a upon dendritic cell maturation: correlation with receptor expression. J. Immunol. 165:2694-2702. 10946300[Abstract/Free Full Text]

Clinical and Vaccine Immunology, March 2007, p. 328-330, Vol. 14, No. 3
1071-412X/07/$08.00+0     doi:10.1128/CVI.00349-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Karlsson, A.
Right arrow Articles by Eriksson, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Karlsson, A.
Right arrow Articles by Eriksson, K.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»